CRISPR Therapeutics

The $3B valuation company that achieved a historic milestone: Casgevy, co-developed with Vertex, became the first CRISPR-based cure approved by the FDA in December 2023 -- a one-time treatment for sickle cell disease. This therapy outperforms standard care, reducing severe pain crises by 100% in trials, compared to a 50% reduction from typical treatments.